Abstracts & publications

There is a world beyond αvβ3: Multimeric ligands for imaging of the integrin subtypes αvβ6, αvβ8,αvβ3 and α5β1 by positron emission tomography
October 2021
Read moreRead more
Preclinical development and characterisation of 99mTc-NM-01 for SPECT/CT imaging of human PD-L1
June 2021
Read moreRead more
European Molecular Imaging Meeting 2021 – 68-Trivehexin enables PET/CT imaging of carcinomas in humans by targeting the “cancer integrin” αvβ6
June 2021
Read moreRead more
European Molecular Imaging Meeting 2021 – Peptide trimers as complex systems: Optimization of pharmacokinetics by simple phenylalanine-tyrosine exchange
June 2021
Read moreRead more
PET/CT imaging of pancreatic carcinoma targeting the “cancer integrin” αvβ6
June 2021
Read moreRead more
PSA-targeted Alpha-, Beta-, and Positron emitting immunotheranostics in murine prostate cancer models and non human primates
April 2021
Read moreRead more
Radiotheranostic targeting of fPSA
February 2021
Read moreRead more
Inter- and intraobserver agreement of the quantitative assessment of [99mTc]-labelled anti-programmed death-ligand 1 (PD-L1) SPECT/CT in non-small cell lung cancer
December 2020
Read moreRead more
Why next generation radiopharmaceuticals will play a key role in the quest for precision medicine
December 2020
Read moreRead more
Open Access Early Phase I Study of a 99mTc-Labeled Anti–Programmed Death Ligand-1 (PD-L1) Single-Domain Antibody in SPECT/CT Assessment of PD-L1 Expression in Non–Small Cell Lung Cancer
September 2019
Read moreRead more
Targeted alpha therapy using short-lived alpha-particles and the promise of nanobodies as targeting vehicle
January 2016
Read moreRead more
Radiolabeled nanobodies as theranostic tools in targeted radionuclide therapy of cancer
July 2014
Read moreRead more
99mTc-Labeled Nanobodies: A New Type of Targeted Probes for Imaging Antigen Expression
June 2008
Read moreRead more

Sign up to our mailing list.

Receive all the latest news from Radiopharm Theranostics.